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263. BIOMARKERS IN OVARIAN CANCER
Rahela Manoli
Scientific adviser: Silvia Stratulat, Associate Professor, Departament of Biochemistry and clinical 
Biochemistry, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Republic of 
Moldova
Introduction: Elucidation of the most frequent biomarkers in ovarian cancer.
Materials and methods: The study was based on the analysis of biographical sources from 2007-
2014.
Discussion results: One of the major challenges in cancer research is the identification of stable 
biomarkers, which can be routinely measured noninvasively in easily accessible samples. Ovarian cancer 
is one such disease that would benefit from improved diagnostic markers. Ovarian cancer is the leading 
cause of death from gynecological malignancy in the western world. One way to facilitate early detection 
of ovarian cancer is through screening, but currently available diagnostic tools, including ovarian cancer 
biomarkers and clinical imaging, lack sufficient specificity and sensitivity for implementation in a 
population-based screening program.
Conclusions: The ability to sensitively and specifically predict the presence of early disease and 
its status, stage and Associated therapeutic efficacy has the potential to revolutionize ovarian cancer 
detection and treatment and to greatly improve the quality of life and survival rates of ovarian cancer 
patients.
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Introduction: Glutathione (GSH) is a tripeptide produced by the liver and has the ability (among 
others) to remove a wide range of toxins, including those produced by heavy metals, alcohol, smoking, 
radiation and cancer chemotherapy. Elevated GSH levels were detected in various types of tumors, along
with high levels of GSH-related enzymes, such as -glutamylcysteine ligase (GCL) and -glutamyl-
transpeptidase (GGT), GSH-transporting export pumps. This makes the neoplastic tissues more resistant 
to chemotherapy. Therefore, the GSH system attracted the attention of scientists as a possible target for 
medical intervention against cancer progression and chemoresistance.
Materials and methods: The presentation represents an extensive literature review and is based 
on relevant scientific articles regarding the subject from medical databases.
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